In June 2020, the Super Sam Foundation invested in Oncoheroes Biosciences, with the aim of advancing the development of new treatments for childhood cancer. Founded in honor of Sam, a courageous rhabdomyosarcoma fighter who ardently wished for better treatment options for "all the kids," the foundation has remained steadfast in its commitment to improving outcomes for children battling cancer.
As Oncoheroes prepares to evaluate the efficacy of its lead compound, volasertib, across five pediatric cancer indications, including rhabdomyosarcoma, the Super Sam Foundation once again steps forward to support our mission. With the latest grant provided by the foundation, the international clinical trial to assess volasertib is now one significant step closer to beginning.
Cassie Santhuff, president and co-founder of the Super Sam Foundation, expresses her support to Oncoheroes, stating, “At Super Sam Foundation, we are committed to funding meaningful research that moves the needle one step closer to saving more lives. Oncoheroes’ innovative approach to their work is both meaningful and effective in the fight to help all the kids who battle cancer. We are, once again, thrilled to partner with the team to continue our support for volasertib. This drug is full-circle for our Foundation, as we wish our Founding Hero, Sam, would have had this drug as an option during his fight 10 years ago. We are deeply appreciative of the incredible work Oncoheroes is doing in the childhood cancer community and excited to support their vital work”.
Together, with the support of partners like the Super Sam Foundation, Oncoheroes can continue to make meaningful strides in advancing pediatric cancer research. We want to express our genuine thanks to the Super Sam Foundation for their generous support and dedication to Oncoheroes' mission.
